Last reviewed · How we verify
NCT03185364
The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD
NA trial testing Sildenafil Citrate in COPD in 46 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 15 June 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sildenafil Citrate (Sildenafil Citrate) — full drug profile →
- Placebo Oral Tablet — full drug profile →
Conditions studied
- COPD — all drugs for COPD →
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
Adults 40 to 85, any sex, with COPD or Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Over half of chronic obstructive pulmonary disease (COPD) patients develop pulmonary hypertension. The current therapy focuses only on the basic disease and there are a lot of controversies about the use of PAH target therapy in group 3 pulmonary hypertension. Our study is to explore whether sildenafil, a pulmonary arterial hypertension (PAH) target drug, could be efficient and safe in improving symptoms and survival of severe pulmonary hypertension caused by COPD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H, Brown Z, Burns A, Williams T. · · 2019 · cited 97× · PMID 30701543 · DOI 10.1002/14651858.cd012621.pub2
Verify or expand the search:
- PubMed search for NCT03185364
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sildenafil Citrate
Trials testing the same drug.
- NCT06178523 — Cost-effective Treatment of Unexplained Infertility · Phase 4 · completed
- NCT05951413 — The Effect of Sildenafil Citrate on Frozen Embryo Transfer Cycles · Phase 2, PHASE3 · unknown
- NCT05846906 — Effect of Oral Sildenafil Citrate on Improvement of Endometrial Thickness · Phase 2, PHASE3 · completed
- NCT04283435 — Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium · Phase 1 · unknown
- NCT04565925 — Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries · Phase 2 · recruiting
Other recruiting trials for COPD
Currently open trials in the same condition.
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
- NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03185364 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 14 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03185364.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing